Back to search
FDAFDA · Food and drugs·Recall number D-0492-2023

Doxazosin 2 mg tablets, packaged in a) 30-count (NDC 70518-1560-00) and b) 90-count bottles (NDC 70518-1560-01), Rx only, Repackaged by: RemedyRepack Inc., Indiana, PA 15701.

Published April 12, 2023 · Recall initiated: March 20, 2023

Summary

FDA records drug Class II recall D-0492-2023, published April 12, 2023 and initiated March 20, 2023. Recalling firm: RemedyRepack Inc.; Status: Terminated; Reported quantity: a) 58 bottles, b) 6 bottles; Lot: Lot #: a) J0665197-120522, Exp. Date 12/31/2023; J0642497-082722, Exp. Date 09/30/2023 J0638552-080922, Exp. Date 08/31/2023. Lot #: b) B1808799-081622, Exp. Date 05/31/2024. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

cGMP Deviations

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
RemedyRepack Inc.
Distributor
RemedyRepack distributed product to consignees nationwide within the United States
Lot
Lot #: a) J0665197-120522, Exp. Date 12/31/2023; J0642497-082722, Exp. Date 09/30/2023 J0638552-080922, Exp. Date 08/31/2023. Lot #: b) B1808799-081622, Exp. Date 05/31/2024
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Doxazosin 2 mg tablets, packaged in a) 30-count (NDC 70518-1560-00) and b) 90-count bottles (NDC 70518-1560-01), Rx only, Repackaged by: RemedyRepack Inc., Indiana, PA 15701. recalled?

Yes. FDA published recall D-0492-2023 on April 12, 2023. Reported hazard: cGMP Deviations

What should I do if I have this product?

Voluntary: Firm initiated · Letter